NextGen Healthcare Selected to Support Fairfax-Falls Church Behavioral Health Expansion

NextGen Healthcare has been selected by the Fairfax-Falls Church Community Services Board (CSB) to enhance its healthcare services for residents in Fairfax County, Virginia, and neighboring cities. The CSB, dedicated to providing lifesaving support for individuals with mental health challenges,…

Read MoreNextGen Healthcare Selected to Support Fairfax-Falls Church Behavioral Health Expansion

Cencora Launches Accelerate Pharmacy Solutions for Hospital and Health System Support

Cencora, a global healthcare company, has unveiled its new initiative, Accelerate Pharmacy Solutions, aimed at enhancing support for hospital and health system customers. This unified portfolio of services is designed to help healthcare organizations optimize their operations and improve their…

Read MoreCencora Launches Accelerate Pharmacy Solutions for Hospital and Health System Support

BrightPath Bio and Cellistic Announce Collaboration for Phase 1 BCMA CAR-iNKT Cell Trial

BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced a new agreement focused on process development and manufacturing. The…

Read MoreBrightPath Bio and Cellistic Announce Collaboration for Phase 1 BCMA CAR-iNKT Cell Trial

Gilead’s Seladelpar Gets Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the approval of seladelpar in treating primary biliary cholangitis (PBC). This treatment, which can…

Read MoreGilead’s Seladelpar Gets Positive CHMP Opinion for Primary Biliary Cholangitis

CHMP Recommends Galderma’s Nemolizumab for Atopic Dermatitis and Prurigo Nodularis

Galderma has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European…

Read MoreCHMP Recommends Galderma’s Nemolizumab for Atopic Dermatitis and Prurigo Nodularis